Yongli Ji

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index612citations96works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(61), Lung Cancer Treatments and Mutations(33), Advanced Breast Cancer Therapies(13), Tissue Engineering and Regenerative Medicine(6), Mesenchymal stem cell research(5)

Publications96 total

Combined impact of body composition and frailty on treatment tolerance and outcomes in patients with endometrial cancer
Gynecologic Oncology·2026
Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy
Neurology·2025
Diagnosis of Primary Aldosteronism without Discontinuation of Interfering Antihypertensive Medications
Current Hypertension Reports·2024· 2 cited
Classification of Neoadjuvant Therapy Response in Patients With Colorectal Liver Metastases Using Contrast-Enhanced Ultrasound—With Histological Pathology as the Gold Standard
Ultrasound in Medicine & Biology·2024· 3 cited
Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy
Neurology·2024· 3 cited
Multimode Ultrasound Model for Predicting the Early Treatment Response of Anti-VEGF Agents Plus Anti-PD-1 Antibody in Patients with Unresectable Hepatocellular Carcinoma
Ultrasound in Medicine & Biology·2024· 4 cited
Abstract GS03-10: Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
Cancer Research·2024
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Table S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Figure S6 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Figure S7 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Table S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Supplemental Text from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Figure S4 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Supplementary Tables S1 to S5 from Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary <i>PIK3CA</i> Mutations
2024Open Access
Figure S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Figure S1 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
Figure S3 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Andreas Varkaris(19), Ermira Pazolli(19), Hakan Günaydin(19), Levi Pierce(19), Qi Wang(17), Alessandro A. Boezio(17), Artemisa Bulku(17), Lucian DiPietro(17), Cary Fridrich(17), Adam Frost(17), Fabrizio Giordanetto(17), Erika Hamilton(17), Katherine Harris(17), Michael Holliday(17), Tamieka L. Hunter(17), Amanda Iskandar(17), Alexandre Larivée(17), Jonathan R. LaRochelle(17), André Lescarbeau(17), Fabien Llambi(17)